Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.

about

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.

Item

http://www.wikidata.org/entity/Q54979668

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@en

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@nl

type

Item

label

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@en

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@nl

prefLabel

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@en

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@nl

P1476

Effectiveness of afatinib afte ...... S768I mutation: a case report.

@en

P2093

Chenyao Sun

http://www.w3.org/2001/XMLSchema#string

Chufan Luo

http://www.w3.org/2001/XMLSchema#string

Hua Duan

http://www.w3.org/2001/XMLSchema#string

Huijuan Cui

http://www.w3.org/2001/XMLSchema#string

Jingyi Zhang

http://www.w3.org/2001/XMLSchema#string

Qiang Li

http://www.w3.org/2001/XMLSchema#string

Wen Shen

http://www.w3.org/2001/XMLSchema#string

Yanmei Peng

http://www.w3.org/2001/XMLSchema#string

Yuqin Qiu

http://www.w3.org/2001/XMLSchema#string

P2860

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

Global cancer statistics, 2012

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

2303-2309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/OTT.S151125

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29731638

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5923252

http://www.w3.org/2001/XMLSchema#string